Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
A.2.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.213NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.213NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.56 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.56 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.39.1.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.39.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.91.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
AY.91.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.14 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.4.14 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.359NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-18756.6US
B.1.1.359NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBC.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Q.2 (Alpha)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Q.2 (Alpha)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BL.1.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BL.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
M.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
M.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
C.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.82 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.82 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.30NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
A.30NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.35NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.36.35NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.23.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.23.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.466.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.466.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.13NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Q.8 (Alpha)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Q.8 (Alpha)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.122.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.122.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.3.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.5.6 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
AY.5.6 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.440NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.440NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.25NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.23.2 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used